Executive Summary
Ultra-low dose products introduce formulation challenges that traditional approaches were not designed to handle. Traditional oral formulations typically include 1 mg to 800 mg of API. But newer, more potent therapies–hormones, vitamin D analogs, targeted APIs, and next-generation biologics–are effective at microgram does (0.25 mg to 10 µg). At that scale, conventional approaches don’t work.
When your API dose is measured in micrograms instead of milligrams, a single formulation misstep can mean the difference between therapeutic success and regulatory rejection.
One study showed that 40% of OTC vitamin D formulations fail to meet content-uniformity standards set by the USP, with actual API recoveries ranging from 8% to 201% of label claims. For ultra-low-dose products, that kind of variability can lead to treatment failure or patient harm.
At Concuir, we have decades of experience developing formulations including ultra-low dose drug products. We know how to turn these high-risk technical challenges into reliable, market-ready products. We have the formulation expertise you need to reduce development risk and accelerate your path to approval.